BSE Live
Dec 29, 16:01Prev. Close
2009.95
Open Price
2043.00
Bid Price (Qty.)
2000.00 (6)
Offer Price (Qty.)
2028.20 (5)
NSE Live
Dec 29, 15:44Prev. Close
2010.60
Open Price
2012.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
2009.70 (452)
| Balance Sheet of Glenmark Pharma (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | |||
| SHAREHOLDER'S FUNDS | |||
| Equity Share Capital | 23.72 | 11.85 | |
| Total Share Capital | 43.72 | 21.85 | |
| Reserves and Surplus | 242.98 | 213.21 | |
| Total Reserves and Surplus | 242.98 | 213.21 | |
| Total Shareholders Funds | 286.70 | 235.06 | |
| NON-CURRENT LIABILITIES | |||
| Long Term Borrowings | 407.43 | 50.04 | |
| Deferred Tax Liabilities [Net] | 38.61 | 29.32 | |
| Other Long Term Liabilities | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 446.05 | 79.36 | |
| CURRENT LIABILITIES | |||
| Short Term Borrowings | 29.30 | 64.45 | |
| Trade Payables | 55.62 | 46.46 | |
| Other Current Liabilities | 13.43 | 15.63 | |
| Short Term Provisions | 9.71 | 12.80 | |
| Total Current Liabilities | 108.07 | 139.34 | |
| Total Capital And Liabilities | 840.82 | 453.77 | |
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| Tangible Assets | 171.85 | 102.66 | |
| Intangible Assets | 37.45 | 35.01 | |
| Capital Work-In-Progress | 12.91 | 24.50 | |
| Other Assets | 0.00 | 0.00 | |
| Fixed Assets | 222.21 | 162.16 | |
| Non-Current Investments | 26.46 | 29.96 | |
| Deferred Tax Assets [Net] | 2.53 | 2.36 | |
| Long Term Loans And Advances | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.64 | |
| Total Non-Current Assets | 251.19 | 195.13 | |
| CURRENT ASSETS | |||
| Current Investments | 0.00 | 0.00 | |
| Inventories | 111.06 | 82.16 | |
| Trade Receivables | 182.10 | 130.48 | |
| Cash And Cash Equivalents | 109.28 | 6.77 | |
| Short Term Loans And Advances | 185.99 | 39.20 | |
| OtherCurrentAssets | 1.20 | 0.03 | |
| Total Current Assets | 589.63 | 258.64 | |
| Total Assets | 840.82 | 453.77 | |
| OTHER ADDITIONAL INFORMATION | |||
| CONTINGENT LIABILITIES, COMMITMENTS | |||
| Contingent Liabilities | 0.46 | 5.11 | |
| CIF VALUE OF IMPORTS | |||
| Raw Materials | 34.74 | 21.99 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | |
| Capital Goods | 8.96 | 7.68 | |
| EXPENDITURE IN FOREIGN EXCHANGE | |||
| Expenditure In Foreign Currency | 29.52 | 15.57 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | |||
| Dividend Remittance In Foreign Currency | 0.04 | 37.73 | |
| EARNINGS IN FOREIGN EXCHANGE | |||
| FOB Value Of Goods | 129.16 | 48.64 | |
| Other Earnings | 0.98 | 0.32 | |
| BONUS DETAILS | |||
| Bonus Equity Share Capital | 15.84 | 3.98 | |
| NON-CURRENT INVESTMENTS | |||
| Non-Current Investments Quoted Market Value | 0.10 | 0.06 | |
| Non-Current Investments Unquoted Book Value | 26.41 | 29.92 | |
| CURRENT INVESTMENTS | |||
| Current Investments Quoted Market Value | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- |
23.12.2025
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
03.12.2025
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015